CRISPR trials in China advance even as research stalls in the U.S.
Jeremy Grinan for STAT Exclusive: A pariah in science, the 'CRISPR babies' researcher gains support from a U.S. cryptocurrency entrepreneur At the core of this funding is a belief driven by escalating competition between China and the West, rising interest in eugenic ideas, and long-standing ethical shortcomings in the culture of international scientific research: That emerging technologies should be allowed to progress unencumbered by safety worries or ethical guardrails. Read more. By Megan Molteni
|
|
 Illustration: Anna Yeo/STAT; Photos: Emrich, Getty Images, AP Exclusive: With boost from RFK Jr. and Tucker Carlson, two chronic disease entrepreneurs vault into Trump's orbit Siblings Calley and Casey Means have gone from relative unknowns to emergent conservative rabble-rousers, laying out a sprawling argument for how polluted health care, government, and science have become with perverse financial incentives. Read more. By Isabella Cueto
 Adobe
As U.S. efforts stall, China pushes ahead with CRISPR treatments for muscular dystrophy Two of the first efforts to treat Duchenne muscular dystrophy with CRISPR gene editing are getting off the ground in China — while similar treatments in the U.S. seems distant. Read more. By Jason Mast In case you missed it... |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2024, All Rights Reserved. | |
|
No comments